The anti-PDL1 antibody drug pembrolizumab is being assessed in the neoantigen vaccine trial NCT03568058 in NSCLC, head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma (cHL) and other solid tumors. The gene discussed is CD274; the disease is classic Hodgkin lymphoma.